Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required)
Grant Opportunity Analysis
The National Institutes of Health intends to publish a Notice of Funding Opportunity to solicit applications for early to definitive clinical trials. Funded projects must test interventions such as drugs, devices, biologics, procedures, behavioral, social, economic, health services, or other biomedical and non-pharmacological approaches that align with the participating NIH Institutes, Centers, and Offices. The initiative will utilize a bi-phasic, milestone-driven R61/R33 award structure, where the R61 phase funds planning activities and the R33 phase supports the clinical trial implementation over a maximum project period of seven years. Eligible applicants include higher education institutions, non-profits, small businesses, governments, and foreign entities, with an estimated synopsis post date of May 31, 2027, and inquiries directed to NIA-NOFO-Scientific@nih.gov.
Eligible Applicants
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Grant Documents
No documents available for this grant.